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要旨 
 
【背景・目的】米国の医療においては、医療の質、医療安全、患者満足度を最
小限の費用の範囲で改善するために、日本の自動車産業で発達した横断的なチ
ームアプローチの概念を臨床現場に導入し、医療効果の改善、費用削減等の成
果に関する報告例が蓄積されつつある。また、薬剤師の医薬品使用プロセスへ
の関与が医療の質の改善や医療費用の削減にもたらす効果についても、幅広く
認識されている。本研究では、日本の代表的医療施設における肺がんを対象と
した外来がん化学療法の医薬品使用プロセスについて、薬剤師、医師、看護師
の相互関係の全体像を定性的に把握し、定量的な医療経済評価研究では捕らえ
にくい薬剤師の役割を明確化することを目的としてケーススタディを実施した。 
【方法】2005 年 7 月の 1 ヶ月間、聖路加国際病院外来点滴センターを対象とし
た参与観察調査及び時間調査を実施した。センターのメンバー構成は医師 1名、
専任薬剤師 1 名、補佐薬剤師 1 名、専任看護師 4 名、事務職 1 名で、センター
のベット数は 15 床である。本調査結果と海外施設の薬剤業務状況を比較できる
ように、American Society of Health-System Pharmacists（ASHP）National 
Surveys 2001-2003 で規定された医薬品使用プロセスに準拠して観察項目を設
定し、その各項目の米国での平均導入・実施率を比較基準として利用した。 
【結果】聖路加国際病院での外来がん化学療法の受診者数は 1日平均約 30 人（最
高 50 人、最小 15 人）であり、受診者全体の 18％が呼吸器内科の外来患者であ
った。外来がん化学療法のレジメンは、呼吸器内科の医師が肺がんを対象とし
て作成し、外来点滴センターのメンバーがピアレビューを行う方法が採用され
ている。2005 年 7 月時点で 20 種類のレジメンが使用されており、抗がん剤と
しては、パクリタキセル、カルボプラチン、塩酸ゲムシタビン、酒石酸ビノレ
ルビン、ドセタキセル、塩酸イリノテカン、塩酸アムルビシン、エトポシドで
あった。また、前投薬は、塩酸ジフェンヒドラミン、リン酸デキサメタゾンナ
トリウム、ファモチジン、塩酸オンダンセトロンが登録されていた。ASHP 調
査結果と比較すると、米国における導入率が 4.3％（2001 年）にとどまってい
るオーダーエントリーシステムが、聖路加国際病院では日常的かつ円滑に利用
されていた。ASHP 調査結果で米国における導入率が 19.5％（2002 年）となっ
ているサテライトファーマシーが、外来点滴センターに導入されており、医師、
薬剤師、看護師のチーム連携を前提とした分散型医薬品供給システムが構築さ
れていた。自動車産業の経済分析で利用されるかんばん方式モデルの概念を利
用して、分散型医薬品供給システムの製品及び情報の流れを分析した結果、調
剤及び薬剤投与のプロセスが前投薬と抗がん剤の各サブプロセスに分割（「モジ
ュール」化）されており、また、薬剤師が常駐するセンター内の調剤スペース
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が図中の在庫点となるように製品と情報の流れが設定されていた。 
患者ごとに抗がん剤と治療指示書を封入した四角形の透明ビニール袋が、日本
の自動車産業で利用されている「かんばん」と同じ機能を果たしており、薬剤
の種類、分量、調剤前と調剤後のプロセスの進行状況等を視覚的に把握するこ
とが可能になっていた。前投薬については、取り揃え所要時間が約 1 分、投与
所要時間が約 30 分でほぼ共通していたが、薬剤師が 100％実施する抗がん剤の
調製所要時間は、最短で酒石酸ビノレルビンの 1 分 51 秒、最長でドセタキセル
の 14 分 14 秒で、選択された薬剤によるばらつきが顕著であった。患者モニタ
リングについて、ASHP 調査結果では各患者固有のデータへのアクセスが増加
しているとする病院の比率が 39.9％（2003 年）であったが、外来点滴センター
の場合、電子診療録システムが導入されており、薬剤師は、各患者の薬歴情報
データとともに外来がん化学療法受診患者のモニタリング業務を、責任をもっ
て実行していた。また、外来点滴センターで見出された薬剤有害事象（ADEs）
は、リスクマネジメント委員会を通じて院内に報告される体制が構築されてい
た。患者教育は、直接的には看護師が対応するが、その資料となる医薬品情報
等のパンフレット類の作成などは薬剤師が主体的に行うことにより、外来がん
化学療法における安全性強化が図られていた。 
【考察】処方及びレジメンのプロセスで観察された、肺がんの外来がん化学療
法専門家チームによるレジメン導入手法は、製造業のチームアプローチによる
品質管理手法である「品質機能展開（QFD）」と同じであり、薬剤師はレジメン
の表現を標準化してわかりやすくすることによって、薬物療法に関連する問題
（MRP）の発生を予防し、潜在的費用の発生を抑制する役割を担っていると考
えられた。また、調剤及び薬剤投与のプロセスで観察された「モジュール」や
「かんばん」の概念は自動車産業の業務改善活動で活用されているものであり、
薬剤師は製造業的な視点から製品の流れと情報の流れを制御することによって、
受診患者の薬剤投与開始までの待ち時間最小化に貢献していると考えられた。
他方、モニタリング及び患者指導のプロセスでは、サービス業的な視点から、
薬剤師が医療情報システムを活用してチーム医療に付加価値を提供する活動が
観察された。以上のことから、外来がん化学療法チームの中で、製造業的な視
点とサービス業的な視点を兼ね備えた医療専門職である点が薬剤師の強みであ
り、製造業やサービス業で開発された経済分析モデルを臨床現場で応用するこ
とにより、医療経済における薬剤師介入の影響度を定量化することが可能であ
ると考えられた。 
【結論】本研究の結果から、薬剤師が臨床現場で外来がん化学療法の医薬品使
用プロセスに関与することによって、レジメンによる業務フローの標準化、製
造業的な業務改善手法による製品の流れや情報の流れの制御、サービス業的な
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医薬品情報提供による安全性強化等、チーム医療の質の改善や薬物療法に関連
する問題（MRP）に付随する費用の抑制が可能であることが示唆された。定性
的調査手法の場合、定量的調査手法に比べて、一般化可能なデータの収集に限
界があり、他施設における再現等には注意を要する。しかしながら、このよう
な研究は、複雑なチーム医療の全体像及び薬剤師の役割を明確化するためには
有効であり、日本の外来がん化学療法に関する定量的評価研究を補完するため
にも必要であると考えられる。 
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ABSTRACT 
 
Objective 
A case study was undertaken to clarify the qualitative picture of 
pharmacist-physician-nurse interactions in medication-use processes for 
outpatient chemotherapy operations in a hospital-based setting in Japan. 
Methods 
An on-site observation and time study was performed at the Blood 
Transfusion Unit of St. Luke's International Hospital during the period July 
1-31, 2005. For comparison of the results with practices outside Japan, the 
observation items of this study were organized in accordance with general 
steps of medication-use process identified in the American Society of 
Health-System Pharmacist (ASHP) National Surveys of Pharmacy Practice 
in Hospital Settings in 2001-2003. 
Results 
In the case study, adoption trends of pharmacy practice in medication-use 
processes seemed to be at relatively the same level as those at hospitals in 
the US, when compared to the results of the ASHP National Surveys in 
2001-2003 as the key benchmarks. The case study also found that the unique 
roles of the chemotherapy pharmacist for both product-focused and 
service-focused responsibilities enabled the outpatient chemotherapy team 
to adopt the same concepts of continuous quality improvement as those in 
the Japanese automotive industry, and that multi-skilled personnel 
development activities for the hospital pharmacist are important to carry out 
the roles in improving quality of care and reducing costs associated with 
preventable medication-related problems. 
Conclusion 
The case study suggests that the pharmacist’s commitment to 
medication-use processes of outpatient chemotherapy at the point of care can 
contribute to improvement in the quality of care and reduction of 
preventable costs associated with medication-related problems (MRPs) in 
team care by controlling product flow and information flow from both 
product-focused and service-focused perspectives. 
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CHAPTER I 
Background and objective 
 
1.1 Introduction 
 
In the Japanese automotive industry, multidisciplinary team approaches 
have been utilized to harmonize production leveling and market 
diversification and have contributed to the efficiency and effectiveness 
improvement. (*1) 
Taiichi Ohno, the founder of the just-in-time system in the Japanese 
automotive industry, noted that the key concepts of the process-focused tools 
included "just-in-time" and "autonomation". 
"Just-in-time" means that, in a flow process, the right parts needed in 
assembly reach the assembly line at the time they are needed and only in the 
amount needed. A tool for managing and assuring just-in-time production is 
called a "kanban", a simple and direct form of communication always located 
at the point where it is needed. In most cases, a kanban is a small piece of 
paper inserted in a rectangular vinyl envelope and carries information 
regarding pickup, transfer, and production.  
"Autonomation", or automation with a human touch, means transferring 
human intelligence to a machine. Autonomation prevents the production of 
defective products, eliminates overproduction, and automatically stops 
abnormalities on the production line allowing the situation to be investigated. 
A tool for managing and assuring autonomation is called  "visual control" or 
management by sight.  A means of visual control is paper-based "standard 
work sheet", containing information with regard to elements of the standard 
work procedure such as cycle time, work sequence and standard inventory.  
The standard work sheet effectively combines materials, workers, and 
machines to produce efficiently. 
In addition, Ohno suggested that autonomation corresponded to the skill and 
talent of individual players while just-in-time was the team-work involved in 
reaching an agreed-upon objective. In the Japanese automotive industry, 
operators acquire a wide range of skills and participate in building up a total 
system in the production plant. Such multi-skilled personnel development 
activities are consistent with the philosophy of "kaizen" or and contribute to 
integration of just-in-time and autonomation at grassroots level. 
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While information technologies have been introduced to assembly lines for 
paperless operations, the Japanese automotive manufacturers continue to 
utilize paper-based tools such as "kanban" and "standard work sheet" for the 
quality and safety improvement and the multi-skilled personnel 
development. Going to a computer screen moves the workers' eyes from the 
real workplace to the virtual screen and may weaken advantages of "visual 
control". 
 
As the automotive industry has tried to improve quality, safety and customer 
satisfaction, the current health care industry is facing challenges to improve 
the quality of care, medication safety and patient satisfaction at lower costs. 
The US health care industry has adopted the multidisciplinary team 
approaches that originated from Japan. Spear (2005) reported that doctors, 
nurses, pharmacists, technicians, and managers increased the effectiveness 
of patient care and lowered its cost by applying the same capabilities in 
operations design and improvement that drive the Japanese automotive 
production system. (*2)   
In addition, the pharmacist's commitment to medication-use processes has 
been widely recognized to be effective for improving the quality of care and 
reducing medication  costs. For example, Bair and Cheminant (1980) 
reported that moving the pharmacist to the patient care unit decreased the 
time that pharmacists spent handling drugs and improved the 
communication with the medical and nursing staff, (*3) and Wadd and 
Blissenbach (1984) reported that a decentralized drug distribution using a 
satellite pharmacy was associated with more efficient use of nursing time 
compared with a centralized drug distribution. (*4) 
Regarding outpatient chemotherapy, the Japanese health care industry has 
adopted a wide range of technologies and tools that originated from the US. 
However, little has been reported on the total picture of 
pharmacist-physician-nurse interactions in medication-use processes in 
Japan, and the pharmacist's role and added value in quality improvement 
and cost reduction might be underestimated by key decision makers on 
health economics such as patients, medical insurance payers and health care 
policy makers. 
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1.2 Objective 
 
This case study was undertaken to clarify the qualitative picture of 
pharmacist-physician-nurse interactions in medication-use processes for 
outpatient chemotherapy operations in a hospital-based setting in Japan.  
 
1.3 Background 
 
St. Luke's International Hospital is a non-profit, full-service hospital with 
520 beds in downtown Tokyo. In 2004, the average inpatient stay was 10.9 
days, and the average number of outpatients was approximately 2,551 per 
day. As of October 2005, staff of the hospital included 250 doctors, 615 nurses, 
21 pharmacists, 199 medical technicians, 64 nurse assistants, and 142 
administration staff.  
In 1998, an integrated hospital information system, including the 
computerized physician order entry (CPOE) system and the pharmacy 
computer system, was renewed. In July 2003, electronic medication 
administration records (MARs) system was implemented. 
The Blood Transfusion Unit is an integral part of outpatient oncology 
practice at the hospital, and it aims to provide the appropriate space for 
outpatient chemotherapy, improving the efficiency and effectiveness in 
quality of care and patient safety, and responding to demands from patients 
and families. The unit receives outpatients between 8:30 AM and 4:00 PM 
every weekday. The integrated hospital information system made it possible 
to establish an exclusive point-of-care drug distribution system with a 
satellite pharmacy and safe dispensing cabinets at the unit. 
As of July 2005, approximately 30 outpatients (max. 50 per day and min. 15 
per day) received chemotherapy in the 15-bed treatment room in the unit 
each day. Of these outpatients, 61% were from the Breast Surgery Dept., 
18% from the Respiratory Medicine Dept., 11% from the Digestive Surgery 
Dept., 5% from the Digestive Internal Medicine Dept., 4% from the 
Hematology Dept. and 1% from the Gynecology Dept. The unit was staffed 
with 1 physician (Unit Director with expertise in hematology), 2 
chemotherapy pharmacists (one chemotherapy-specific pharmacist and one 
general pharmacist), 4 oncology nurse specialists and a clerical staff.   
Among healthcare practices for cancer diseases at the unit, outpatient 
 -11- 
chemotherapy practices for lung cancer were focused upon in the case study.  
According to the National Vital Statistics, lung cancer has been the leading 
cause of cancer death in Japan since 1998 and the treatment of lung cancer 
still heavily depends on inpatient care. From the economic points of view, the 
potential impact of quality and safety improvement in outpatient 
chemotherapy practices for lung cancer seems larger than for other cancers. 
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CHAPTER 2 
Methods 
 
2.1 Methods 
 
Guerrero et al. (1995) suggested that measuring the amount of time that 
pharmacy teams spent on work activities provided a means of improving 
organizational inefficiencies in order to give the pharmacists more time for 
patient care. (*5) And Runciman (2002) suggested that qualitative research 
would be well suited to probing the complex factors behind human errors and 
system failure in health care. (*6) 
To clarify the qualitative picture of pharmacist involvement in the team 
medication process of outpatient chemotherapy for lung cancer, on-site 
observation and a time study was performed at the Blood Transfusion Unit of 
the St. Luke's International Hospital. With the approval of the Ethics 
Committee of the hospital, researchers made observations at the outpatient 
chemotherapy center during the period of July 1-31, 2005.  
 
2.2 Observation items 
 
For comparison of the results with pharmacy practices outside Japan, the 
observation items of this study were organized in accordance with the 
general steps for medication-use processes identified in the American Society 
of Health-System Pharmacist (ASHP) National Surveys of Pharmacy 
Practice in Hospital Settings in 2001-2003. (*7, *8, *9)  Targeting pharmacy 
directors in the US, the ASHP surveys were designed on the basis of 
three-part series beginning in 2001 and concluding in 2003. The 2001 survey 
was concerned with prescribing and transferring steps, the 2002 survey was 
concerned with dispensing and administration steps, and the 2003 survey 
was concerned with monitoring and patient education steps. When combined, 
the 2001-2003 surveys represented composite picture of the role of 
pharmacists in managing and improving the medication-use process. 
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Figure 1 shows the observation items for the study.  
Figure 1. Observation items of medication-use process
(1) Prescribing and 
transcribing
(2) Dispensing and 
administration
(3) Monitoring and 
patient education
1) Activities of the pharmacy and therapeutics (P&T) committee
2) Use of clinical practice guidelines
3) Medication-use evaluation activities 
4) Use of trend data to improve prescribing
5) Extent of pharmacist consultations
6) Provision of drug information to prescribers
7) Evaluation of medication orders
8) Use of prescriber order-entry systems
9) Actions taken to ensure accurate transcription of medication orders
1) Patient drug distribution system
2) Use of technology in drug distribution 
3) Medication preparation and dispensing
4) Drug administration
5) Use of medication administration records
6) Collaboration in pharmacy operations and preparation activities 
7) Quality improvement activities
1) Time pharmacists spend monitoring medication therapy
2) Trends in pharmacists' monitoring of medication therapy
3) Services and medications monitored
4) Steps taken to improve medication therapy monitoring
5) Methods used to monitor patients' adverse drug events (ADEs)
6) Internal and external ADE reporting
7) Pharmacists' patient education and counseling responsibility
(Adapted from American Society of Health-System Pharmacists（ASHP）National Surveys 2001-2003)
[Medication-use process] [Observation item]
 
 
The prescribing and transcribing steps included activities of the pharmacy 
and therapeutics (P&T) committee, use of clinical practice guidelines, 
medication-use evaluation activities, use of trend data to improve 
prescribing, extent of pharmacist consultations, provision of drug 
information to prescribers, the evaluation of medication orders, use of 
prescriber order-entry systems, and actions taken to ensure accurate 
transcription of medication orders. The dispensing and administration steps 
included patient drug distribution system, use of technology in drug 
distribution, medication preparation and dispensing, drug administration, 
use of medication administration records, collaboration in pharmacy 
operations and preparation activities, and quality improvement activities. 
The monitoring and patient education steps included time pharmacists 
spend monitoring medication therapy, trends in pharmacists' monitoring of 
medication therapy, services and medications monitored, steps taken to 
improve medication therapy monitoring, methods used to monitor patients' 
adverse drug events (ADEs), internal and external ADE reporting, and 
pharmacists' patient education and counseling responsibility. 
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CHAPTER 3 
Results 
 
3.1 Introduction 
 
From on-site observation study, Figure 2 presents workflow of outpatient 
chemotherapy for lung cancer at the Blood Transfusion Unit in the St. Luke's 
International Hospital.  
Check-in at Returning 
Outpatient Reception
Test at blood collection 
room
Receive consultation at 
Respiratory Dept. 
Visit reception at Blood 
Transfusion Unit 
Receive administration 
of premedication
Receive adminstration 
of chemotherapy drug
Pay medical fee
Figure 2. Workflow of outpatient chemotherapy for lung cancer
Physician Nurse PharmacistOutpatient
Enter treatment order form
Computer
Print and preview treatment 
order sheet (Red color)
Prepare and store chemotherapy drug 
Prepare and store  i.v. 
administration devices and drug 
labels
Chemotherapy drug set
(Treatment order sheet 
and chemotherapy drug)
Premedication drug set
(Treatment sheets, i.v. 
administration devices 
and drug labels）
Confirm test results and 
decide administration
Audit prescription and 
treatment order  in 
accordance with protocol and 
drug history 
Dispense chemotherapy drug  
in safety cabinet
Confirm patient name, 
premedication drug and drug 
label in accordance with 
prescription and treatment sheet Reconfirm prescription and 
treatment sheet in accordance 
with protocol and MARs
Confirm patient name and 
chemotherapy dose in 
accordance with prescription 
and treatment order
Confirm patient name and 
chemotherapy dose in accordance 
with prescription and treatment 
order
Wear personal  protective 
equipment, clean safety 
cabinet and prepare for 
dispensing
Provide nurse with dispensed 
chemotherapy drug
Receive dispensed 
chemotherapy drug from 
pharmacist
Dispose used devices and 
liquid residue
Enter drug history of the 
treatment date
The day of  preorder entering
The day before treatment
The day of treatment
Print and preview treatment 
order sheet (Blue color)
 
 
And, for comparison with the results of the ASHP national surveys in 
2001-2003 as key benchmarks, Table 1 illustrates the pharmacy practice 
adopted in the medication-use process for outpatient chemotherapy in the 
Blood Transfusion Unit. For comparison between the case study and 
hospitals in the US, percentages of adopting hospitals in the ASHP surveys 
are also shown in Table 1. 
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Table 1. Adopted pharmacy practice in medication-use process 
for outpatient chemotherapy
Medication-use
process
Pharmacy practice adopted by the Blood Transfusion Unit Percentage of
adopting hospitals
in ASHP national
surveys (Year)
1) Having the pharmacy and therapeutics (P&T) committee 99.3% (2001)
2) Using clinical practice guidelines 68.8% (2001)
3) Having medication-use evaluation activities 77.9% (2001)
4) Using trend data to improve prescribing on developing formulary decisions 69.5% (2001)
5) Having pharmacist consultations on drug information 91.9% (2001)
6) Having pharmacists routinely provide drug information to prescribers 98.0% (2001)
7) Reconcile MARs and pharmacy patient profiles at least daily 63.2% (2001)
8) Using computerized prescriber order-entry (CPOE) systems 4.3% (2001)
9) Double-checking chemotherapy regimen 72.1% (2001)
1) Having decentralized drug distribution system 19.5% (2002)
2) Using point-of-care-activated devices for small-volume injectable products 82.0% (2002)
3) Requiring pharmacists to review and approve all medication orders before drug 79.4% (2002)
4) Giving primary responsibility for drug administration to nurses 99.7% (2002)
5) Using computer-generated medication administration records 64.4% (2002)
6) Evaluating pharmacy dispensing errors discovered by nurses 86.1% (2002)
7) Evaluating the accuracy of the pharmacy patient medication record 58.4% (2002)
1) Increase in the amount of time clinical-distributive pharmacists devoted to monitoring
medication therapy
77.7% (2003)
2) Having a process for routine patient-profile monitoring by pharmacists 67.6%(2003)
3) Transfer of electronic information when patients are transferred between inpatient and
outpatient settings
78.0%(2003)
4) Increased access to patient-specific data 39.9%(2003)
5) Internal reporting of  adverse drug events (ADEs) through the Risk Management 53.7%(2003)
6) Having an interdisciprinary team including a pharmacist for leading medication-use 85.5%(2003)
7) Giving primary responsibility for communication with outpatient regarding patient
education and counseling to nurses
87.9%(2003)
(1) Prescribing
and
transcribing
(2) Dispensing
and
administration
(3) Monitoring
and patient
education
 
 
3.2 Findings from the case study 
 
In accordance with Figure 1, Figure 2 and Table 1, the findings from the case 
study are described in 3.2.1, 3.2.2 and 3.2.3. 
 
3.2.1 Findings in prescribing and transcribing steps 
 
As shown in Table 1, of 9 items of prescribing and transcribing steps in the 
ASHP surveys, 9 items were adopted for outpatient chemotherapy at the 
Blood Transfusion Unit. While percentage of hospitals using computerized 
prescriber order-entry (CPOE) systems in ASHP national surveys (2001) was 
4.3%, the St. Luke’s International Hospital implemented and utilized CPOE 
system for outpatient chemotherapy. 
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With regard to using clinical practice guidelines, treatment regimens made a 
role of standardized guidelines in the case study. Figure 3 illustrates 
implementation cycle of treatment regimens of outpatient chemotherapy for 
lung cancer.  
Physicians of the 
Respiratory Medicine 
Dept. develop 
treatment regimens of 
outpatient 
chemotherapy for 
lung cancer
All team members of 
the outpatient 
chemotherapy unit are 
involved in review and 
implementation of 
new regimens
Pharmacists
Feedback
Role of pharmacists
1) Standardize the expressions to be used for reduction of 
medication errors
2) Routinely explore the pharmacy computer system and 
other resources online/offline and provide drug-related 
information to physicians and nurses
Figure 3. Implementation cycle of treatment regimens of 
outpatient chemotherapy for lung cancer
 
 
Treatment regimens of outpatient chemotherapy for lung cancer were 
developed by physicians from the Respiratory Medicine Dept. and were 
distributed to the Blood Transfusion Unit.  
While all team members of the outpatient chemotherapy unit were involved 
in review and implementation of new regimens, pharmacists took care of 
standardizing the expressions to be used for reduction of medication errors. 
In addition, physicians and nurses routinely asked chemotherapy 
pharmacists to provide drug-related information regarding not only clinical 
outcomes but also economic issues, such as drug costs. The pharmacists 
searched the pharmacy computer system and other online/offline resources 
and provided drug-related information to other professionals. 
As of July 2005, 20 kinds of regimens were used for outpatient chemotherapy 
of lung cancer at the unit. 
Table 2 presents chemotherapy drugs and premedication drugs listed on 
treatment regimens of outpatient chemotherapy for lung cancer.  
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Table 2. Chemotherapy drugs and premedication drugs listed on treatment 
regimens of outpatient chemotherapy for lung cancer (as of July 2005)
Regimen name Chemotherapy drug Premedication drug
1) Weekly paclitaxel single therapy paclitaxel
2) Weekly paclitaxel＋radiotherapy paclitaxel
3) Paclitaxel＋CBDCA paclitaxel, carboplatin
4) Weekly paclitaxel＋CBDCA＋radiotherapy paclitaxel, carboplatin
5) Gemcitabine single therapy gemcitabine hydrochloride
6) Gemcitabine＋CBDCA gemcitabine hydrochloride, carboplatin
7) Vinorelbine single therapy vinorelbine ditartrate
8) Vinorelbine＋Gemcitabine vinorelbine ditartrate, gemcitabine hydrochloride
9) Vinorelbine＋CBDCA vinorelbine ditartrate, carboplatin
10) Weekly docetaxel single therapy docetaxel
11) Gemcitabine＋docetaxel gemcitabine hydrochloride, docetaxel
12) Vinorelbine＋CBDCA＋radiotherapy vinorelbine ditartrate, carboplatin
13) Docetaxel＋CBDCA docetaxel, carboplatin
14) Triweekly docetaxel single therapy docetaxel
15) Biweekly docetaxel single therapy docetaxel
16) CBDCA＋VP-16 carboplatin, etoposide
17) Weekly CPT-II＋CBDCA irinotecan hydrochloride, carboplatin
18) Weekly CPT-II＋CBDCA＋radiotherapy irinotecan hydrochloride, carboplatin
19) Weekly CPT-II monotherapy irinotecan hydrochloride
20) Amrubicin single therapy amrubicin hydrochloride
diphenhydramine hydrochloride,
dexamethasone sodium
phosphate, famotidine,
ondansetron hydrochioride
dexamethasone sodium
phosphate, famotidine,
ondansetron hydrochioride
 
 
The chemotherapy drugs included paclitaxel, carboplatin, gemcitabine 
hydrochloride, vinorelbine ditartrate, docetaxel, irinotecan hydrochloride, 
amrubicin hydrochloride and etoposide. The premedication drugs for 
chemotherapy included diphenhydramine hydrochloride, dexamethasone 
sodium phosphate, famotidine, and ondansetron hydrochioride. 
 
The pharmacists were also involved in medication-use evaluation activities 
to improve the procedure of prescribing. Pharmacist consultations on issues 
such as dosage adjustment and adverse drug effects were provided to the 
physicians responsible for prescribing in the Respiratory Medicine Dept. 
Regarding transcribing, the computerized physician order entry (CPOE) 
system and electric medication administration records (MARs) were 
implemented in the hospital. However, the pharmacy computer system was 
not linked to CPOE and required reentry of medication orders. Each day 
before treatment, pharmacists printed, reviewed and double-checked the 
treatment order sheets for verification with CPOE and pharmacy patient 
profiles in preparation for dispensing.  
In the hospital, a cross-functional lung cancer medication team was 
developed and played the role of an information-sharing community for 
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patient-focused chemotherapy. The team was facilitated by physicians of the 
Respiratory Medicine Dept. and pharmacists and nurses in both inpatient 
and outpatient care, including the Blood Transfusion Unit. The team 
organized monthly case conferences, internal seminars and other activities. 
 
3.2.2 Findings in dispensing and administration steps 
 
As shown in Table 1, of 7 items of dispensing and administration steps in the 
ASHP surveys, 7 items were adopted for outpatient chemotherapy at the 
Blood Transfusion Unit. While percentage of hospitals having decentralized 
drug distribution system in ASHP national surveys (2002) was 19.5%, the St. 
Luke’s International Hospital adopted an exclusive decentralized drug 
distribution system for outpatient chemotherapy. 
 
The certified pharmacy technician system is not adopted in Japan, and 
Japanese pharmacists must cover all dispensing tasks. In other words, 
Japanese pharmacists tend to be more product-oriented with technical 
knowledge and skills than those in other countries. 
While a centralized medication system at the Pharmaceutical Dept. had been 
used for inpatients in St. Luke's International Hospital, at the Blood 
Transfusion Unit, a point-of-care drug distribution system with a satellite 
pharmacy and safe dispensing cabinets was adopted to meet the demands of 
time-sensitive outpatients towards just-in-time care delivery.  
In general, decentralized medication systems have the advantage of shorter 
waiting times for outpatients with point-of-care dispensing. Challenges in 
the point-of-care medication systems include requirements of prescribers for 
multi-kind and small quantity dispensing with a variety of chemotherapy 
regimens. Futhermore, in some cases, the outpatient may cancel an 
appointment on the day of treatment and the cancellation may generate 
high-cost waste.  
 
Using kanban-style model developed in the Japanese automotive industry, 
Figure 4 presents product and information flow chart of the point-of-care 
drug distribution system for outpatient chemotherapy. 
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Product flow: 
Based on lead time for dispensing of chemotherapy drug, dispensing schedule is 
assigned at the centralized pharmacy. 
Out-
patient
Demand forecast
Premedication drug
dispensing
Stock 
point
Stock 
point
Chemotherapy drug
dispensing
Chemotherapy drug
preparation
（→pharmacist）
Stock 
pointPremedication drug
preparation
(→ nurse)
Stock 
point Premedication drugadministration
Chemotherapy
drug
administration
【The day of outpatient’s treatment】【The day before appointment 】
Feedback from 
nurse: signal of 
starting 
premedication
(Face-to-face)
Physician responsible 
for prescribing
Information flow:
<Nurse-driven time management> 
[Blood Transfusion Unit ]
Treatment 
order review 
by pharmacist
(via computer）
Feedback from 
nurse: signal of 
finishing 
premedication
(Face-to-face)
<Pharmacist-driven time management >
Stored place of 
drugs to be used
Treatment 
order sheet
(via computer） (via computer）
Figure 4. Product and information flow chart of decentralized drug distribution 
system for outpatient chemotherapy (using kanban-style model)  
（kanban）
 
    
To meet fluctuations in outpatient demand, the Blood Transfusion Unit 
adopted the same kind of operating methods as those utilized in the 
Japanese automobile industry. The medications for outpatient chemotherapy 
were divided into a standardized chemotherapy premedication set and a 
customized chemotherapy medication set. This was originally from the 
"module" concept, defined as "the parts group made into the sub-system from 
a certain specific viewpoint", and it is widely utilized for process 
improvement in the manufacturing industries. (*10) 
 
The first chemotherapy premedication set was composed of premedication 
drugs, i.v. administration devices and drug labels. The premedication sets 
were commonly listed and used in treatments not only for lung cancer but 
also other types of cancer. Based on treatment order sheets, the 
premedication sets were arranged by nurses according to the opening time of 
the unit.  
The second chemotherapy medication set was composed of chemotherapy 
drug, medication order sheet and rectangular transparent bag. The 
treatment order sheet and chemotherapy drug were bundled into the 
rectangular transparent bag. The bag, which carried information about types 
 -20-
and quantities of drugs, regimen and product labeling, always accompanied 
the chemotherapy drug, and served as an essential communications tool for 
just-in-time dispensing and administration at the unit. This concept seemed 
to be the same as "kanban" in the Japanese automotive industry, playing the 
role of providing the information that connects the earlier and later 
processes at every level and contributing to continuous quality improvement. 
(*1) Based on treatment sheets, the pharmacists arrange the chemotherapy 
medication sets the day before the outpatient's appointment.    
 
Regarding the premedication set, a team of two nurses or a 
pharmacist-nurse team checked what was required before dispensing the 
medication. Each step of the premedication process was designed in every 
aspect to offer the administration needed at the time needed.  
The standard cycle time of preparation for premedication was approximately 
1 minute, and that of administration of premedication was approximately 30 
minutes, based on the administration of diphenhydramine hydrochloride.  
Regarding the chemotherapy medication set, the two-pharmacist team or the 
pharmacist-nurse team checked what was required before dispensing 
medication. When starting to administer premedication to each patient, 
team nurses provided the pharmacists with signal of starting premedication 
through face-to-face communications at the point of care. After receiving the 
signal, the pharmacists prepared for dispensing of the chemotherapy drugs 
so that dispensing task could be completed before starting time of 
chemotherapy drug administration.  
From time study, Table 3 shows average cycle time of chemotherapy drug 
dispensing in accordance with treatment regimens of outpatient 
chemotherapy for lung cancer.  
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Regimen name Chemotherapy drug Standard dose
(AUC: Area
under the curve)
Average cycle
time of
dispensing
1) Weekly paclitaxel single therapy paclitaxel 60～80mg/m2 1 min. 57 sec.
2) Weekly paclitaxel＋radiotherapy paclitaxel 30mg/m2 1 min. 57 sec.
paclitaxel 60～80mg/m2 1 min. 57 sec.
carboplatin AUC＝4～6 3 min. 00 sec.
paclitaxel 30～40mg/m2 1 min. 57 sec.
carboplatin AUC＝2 3 min. 00 sec.
5) Gemcitabine single therapy gemcitabine hydrochloride 1000mg/m2 2 min. 26 sec.
gemcitabine hydrochloride 800～1000mg/m2 2 min. 26 sec.
carboplatin AUC＝4 3 min. 00 sec.
7) Vinorelbine single therapy vinorelbine ditartrate 25～30mg/m2 1 min. 51 sec.
vinorelbine ditartrate 20～25mg/m2 1 min. 51 sec.
gemcitabine hydrochloride 800～1000mg/m2 2 min. 26 sec.
vinorelbine ditartrate 20～25mg/m2 1 min. 51 sec.
carboplatin AUC＝4～6 3 min. 00 sec.
10) Weekly docetaxel single therapy docetaxel 35～40mg/m2 14 min. 14 sec.
gemcitabine hydrochloride 800～1000mg/m2 2 min. 26 sec.
docetaxel 60mg/m2 14 min. 14 sec.
vinorelbine ditartrate 15～20mg/m2 1 min. 51 sec.
carboplatin AUC＝2 14 min. 14 sec.
docetaxel 60mg/m2 14 min. 14 sec.
carboplatin AUC＝4 3 min. 00 sec.
14) Triweekly docetaxel single
therapy
docetaxel 60～70mg/m2 14 min. 14 sec.
15) Biweekly Docetaxel single
therapy
docetaxel 25～40mg/m2 14 min. 14 sec.
carboplatin AUC＝4～6 3 min. 00 sec.
etoposide 100mg/m2 2 min. 00 sec.
irinotecan hydrochloride 60mg/m2 2 min. 22 sec.
carboplatin AUC＝5 3 min. 00 sec.
irinotecan hydrochloride 50mg/m2 2 min. 22 sec.
carboplatin AUC＝2 3 min. 00 sec.
19) Weekly CPT-II monotherapy irinotecan hydrochloride 60～100mg/m2 2 min. 22 sec.
20) Amrubicin single therapy amrubicin hydrochloride 35～45mg/m2 2 min. 30 sec.
3) Paclitaxel＋CBDCA
4) Weekly paclitaxel＋CBDCA＋
radiotherapy
6) Gemcitabine＋CBDCA
13) Docetaxel＋CBDCA
16) CBDCA＋VP-16
17) Weekly CPT-II＋CBDCA
18) Weekly CPT-II＋CBDCA＋
radiotherapy
8) Vinorelbine＋gemcitabine
9) Vinorelbine＋CBDCA
11) Gemcitabine＋docetaxel
12) Vinorelbine＋CBDCA＋
radiotherapy
Table 3. Average cycle time of  
chemotherapy drug dispensing
 
 
The standard cycle time for chemotherapy drug dispensing differed 
according to the type of medication drug: a minimum of 1 minute 51 seconds 
for vinorelbine ditartrate and a maximum of 14 minutes 14 seconds for 
docetaxel with normal saline. 
In order to decrease the waiting time for outpatients, the pharmacists 
adjusted the times for dispensing chemotherapy drugs and the nurses 
adjusted the times for administration. Fine adjustments of waiting times by 
pharmacist-nurse team collaboration were unique to the point-of-care drug 
distribution system and significantly contributed to the improvement in 
patient satisfaction. In the event that any drug-related problem occurred 
incurred with an outpatient at the point of care, the pharmacists were able to 
immediately stop product flow and communicate with other team members 
for trouble shooting. Regarding the checking unit dose dispensed by the 
pharmacists, double-check systems were conducted by the pharmacists and 
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the nurses.  
 
3.2.3 Findings in monitoring and patient education steps 
 
As shown in Table 1, of 7 items of monitoring and patient education steps in 
the ASHP surveys, 7 items were adopted for outpatient chemotherapy at the 
Blood Transfusion Unit. While percentage of hospitals with increased access 
to patient-specific data in ASHP national surveys (2003) was 39.9%, the St. 
Luke’s International Hospital utilized patient-specific data in MARs and 
pharmacy patient profile in the pharmacy computer system for outpatient 
chemotherapy. 
At the Blood Transfusion Unit, the chemotherapy pharmacists regularly 
monitored the medication therapy for outpatients. Patient-profile monitoring, 
including review of MARs and pharmacy patient profile, was conducted 
following processing of the medication order. The pharmacists gained 
experience in both technical and clinical tasks through a job rotation system 
within the Pharmaceutical Dept., and this contributed to quick and in-depth 
monitoring for team-performance improvement at the Blood Transfusion 
Unit. 
Regarding adverse drug events (ADE) monitoring and reporting, the hospital 
established a Risk Management Committee and controlled medical safety 
management, including internal incident reporting from health professionals 
in the hospital. Under the committee, the Medical Safety Leader Meeting 
handled safety promotion activities, and the Blood Transfusion Unit was 
involved in those activities.  
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Figure 5 presents internal reporting flow of adverse drug events (ADEs) 
through the Risk Management Committee. 
Risk Management
Committee
（Review）
Medical Safety 
Leader Meeting 
Blood 
Transfusion Unit 
Medical Safety 
Management 
Office 
Hospital Executive 
Meeting
(Report/approval)
Risk 
Management 
Report
(Monthly)
PharmacistPharmacist
Pharmacist
Pharmacy 
patient 
profile
MARs
Adverse drug 
events 
（ADEs）
Outpatient
Figure 5. Internal reporting flow of  adverse drug events (ADEs) 
through the Risk Management Committee  
(Monitoring)
 
 
At the Blood Transfusion Unit, nurses had more opportunities for contact 
with outpatients during chemotherapy administration and they provided 
patient education and counseling. In addition, the pharmacists supported 
the nurses’ activities by providing detailed drug information from the 
pharmacy computer system and developing patient education materials. 
However, when patients with lung cancer were transferred between 
inpatient and outpatient settings, the pharmacists counseled the patients 
directly. SIS and NHI compensated for the pharmacist counseling as part of 
inpatient medication fees. 
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CHAPTER 4 
Discussion 
 
4.1 Introduction 
 
From benchmarking in the case study shown in Table 1, adoption trends for 
pharmacy practice in medication-use process at the outpatient chemotherapy 
unit seemed to be at relatively the same level as those at hospitals in the US. 
The case study also found that outpatient chemotherapy team in the 
Japanese health care setting adopted and utilized the same concepts of 
continuous quality improvement as those in the Japanese automotive 
industry, and that pharmacists made a unique role in the multidisciplinary 
team care. 
 
4.2 Models to quantify values of pharmacist activities in multidisciplinary 
team care of outpatient chemotherapy 
 
From the viewpoints of health economics, traditional cost-effective analysis 
models require objective evidence of improvements in simplified outcome and 
seem to have weakness in identifying direct and indirect impacts of 
pharmacists towards complicated outpatient chemotherapy team. In 
particular, development and implementation of alternative approaches is 
required to quantify outcomes and evidence on medical safety improvement. 
Based on the results of the case study, candidate models for economic 
evaluation are discussed in accordance with steps of medication-use process 
in 4.2.1, 4.2.2 and 4.2.3. 
 
4.2.1 Quality function deployment in prescribing and transcribing steps 
 
Regarding prescribing and transcribing steps, standardized chemotherapy 
treatment regimens have been developed in diverse clinical departments and 
have been implemented into a single outpatient-specific unit in the St. 
Luke's International Hospital.  The multidisciplinary members themselves 
implemented the idea of "quality function deployment (QFD)", a conceptual 
map that provides a means for interfunctional planning and communications 
developed in Japanese manufacturing industries, on a consensus basis to 
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standardize operations for the quality of care, medication safety and patient 
satisfaction.  
According to Hauser et al. (1988), QFD was originated in 1972 at 
Mitsubishi’s Kobe shipyard site, then developed by Toyota and its suppliers, 
and has been used by the Japanese manufacturers. (*11) As a set of planning 
and communication routines, QFD focuses and coordinates skills within an 
organization, first to design, then to manufacture and market goods that 
customers want to purchase and will continue to purchase. The foundation of 
QFD is the belief that products should be designed to reflect customer’s 
desires and tastes and marketing people, design engineers, and 
manufacturing staff must work closely together from the time a product is 
first conceived. From the economic viewpoints, qualitative and quantitative 
case studies were conducted at Toyota, and Sullivan (1986) reported that 
implementation of QFD contributed to a 20% reduction in start-up costs on 
the launch of new van in October 1979, a 38% reduction in November 1982 
and a cumulative 61% reduction in April 1984 at Toyota Auto Body. (*12) 
 
Figure 6 illustrates comparison of the case study to QFD in the Japanese 
automotive industry. While researchers, designers, production engineers and 
marketing staff work together to develop a new car from the 
customer-centered viewpoints in an automotive company, physicians, 
pharmacists and nurses seem to work together to develop a new regimen 
from the patient-centered viewpoints in the St. Luke’s International 
Hospital.  
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Figure 6. Comparison of the case study to quality function deployment (QFD) 
in the Japanese automotive industry  
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Kohler et al. (1998) emphasized the importance of easy-to-understand 
expressions and nomenclature of clinical practice guidelines for cancer 
treatment in order to reduce medication errors. (*13) The identification and 
usage of technical terms in regimens were varied and differed according to 
the clinical department and cross-department standardization of expressions 
and nomenclature was necessary to prevent medication errors at the point of 
care.  
Through cross-departmental and cross-professional communications on a 
daily basis, the chemotherapy pharmacists were trained on the job to 
experience both technical and clinical practices, and showed competence in 
developing and adjusting comprehensive expressions for use with a diverse 
oncology practitioners. This strength seems to be a significant contribution 
to other members of the outpatient chemotherapy team. It would appear that 
the pharmacists’ commitment to development of standardized chemotherapy 
treatment regimens seems to enhance economic improvement by reducing 
hidden costs associated with preventable medication-related problems 
(MRPs). 
QFD models in the Japanese automotive industry have focused on integrated 
approaches of qualitative and quantitative research and seem well suited to 
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probing unique roles of chemotherapy pharmacists for economic evaluation.  
Figure 7 illustrates conceptual QFD framework of team care in outpatient 
chemotherapy for future economic evaluation study.  
Figure 7. QFD framework of team care in outpatient chemotherapy
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It seems that pharmacists can enhance standard specifications and standard 
procedures by controlling product flow and information flow continuously at 
the point of care and contribute to economic improvement in the fields of 
outpatient chemotherapy. As the next step, it is recommended that impact 
of standard specifications and standard procedures towards clinical and 
economic outcomes be examined. 
 
4.2.2 Kanban-style model in dispensing and administration steps 
 
Regarding dispensing and administration steps, the chemotherapy 
treatment regimens with comprehensive expressions led to simplified 
treatment order sheets, and were used by physicians, pharmacists, nurses 
and clerical staff. Each order sheet contained an appropriate volume of 
information for instant recognition and operations management by sight. 
Moreover, by use of the rectangular transparent bag with the treatment 
order sheet and chemotherapy drug, the actual progress of chemotherapy 
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operations in comparison to the daily drug distribution schedule was always 
visible.  
Hendershot et al. (2005) reported that shorter waiting times in outpatient 
chemotherapy administration were linked to improvement in outpatient 
satisfaction (*14). With the "kanban" bag, the chemotherapy pharmacists 
were in the position to control both product flow and information flow during 
dispensing and administration steps at the point of care. Our case study 
indicated that members of the outpatient chemotherapy team aimed to 
minimize waiting times between premedication drug administration and 
chemotherapy drug administration by organizing production flow and 
information flow. Control of product flow, knowledge and experience related 
to physical, chemical and biological backgrounds seems important, and 
control of the information flow related to multidisciplinary communications 
in face-to-face and interactive methods seem important for the pharmacists.  
 
In the present case study, the roles of the chemotherapy-specific pharmacist 
were divided into two perspectives. From a product-focused perspective, the 
pharmacist manages the product flow in the dispensing and administration 
steps, aiming to control the production and distribution costs. Meanwhile, 
from a service-focused perspective, the pharmacist plays the role of a 
multidisciplinary coordinator of information flow in the medication-use 
process, aiming to reduce medication-related problems (MRPs) and 
therapeutic failure. 
It seems that the unique roles of the chemotherapy pharmacist composed of 
multi-focused perspectives enabled the outpatient chemotherapy team to 
adopt the "module" concept in a workflow and utilize a simplified "kanban" 
concept for the treatment order sheets. In addition, the multi-skilled 
personnel development activities for the hospital pharmacist appear 
important in developing these effective roles. 
 
For comparison with Figure 4, Figure 8 illustrates a product and information 
flow model of centralized drug distribution system for outpatient 
chemotherapy. Based on an example of centralized drug distribution system 
used for inpatient chemotherapy in the St. Luke’s International Hospital, the 
model in Figure 8 was developed. 
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Figure 8. Product and information flow model of centralized drug distribution 
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Centralized drug distribution system adopts a batch flow method with buffer 
inventories, and pharmacists and nurses work independently in separate 
place. While there seems little difference between centralized and 
decentralized drug distribution systems regarding drug and personnel costs, 
centralized drug distribution system has weakness in a lack of face-to-face 
communication between pharmacists and nurses on a real-time basis. In 
addition, the batch flow method seems to have a risk of generating high-cost 
waste in case of cancellation on the day of treatment. 
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Using kanban-style model, Figure 9 presents pull-push integration system in 
dispensing process of outpatient chemotherapy.  
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Figure 9. Pull-push integration system in dispensing process of 
outpatient chemotherapy (using kanban-style model) 
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Push system model can be applied to dispensing process of premedication 
drug that requires simplified work, and pull system model can be applied to 
dispensing process of chemotherapy drug that requires complicated work. On 
the other hand, push system model can be applied to dispensing process of 
premedication and chemotherapy drug under centralized drug distribution 
system shown in Figure 8.  
In the Japanese automotive industry, push system model has been used for 
mass production lines, and pull system model has been used for customized 
production lines. Pull-push integration system model is combination of push 
system and pull system and has been adopted by Toyota for production of 
many models in small quantities. Economic advantages of pull-push 
integration system in efficiency and effectiveness have been suggested 
through qualitative and quantitative studies. (*15) 
It seems that economic advantage of pharmacist activities with decentralized 
drug distribution system in dispensing and administration steps can be 
examined by applying pull-push integration system model.  
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4.2.3 SECI model in monitoring and patient education steps 
 
Regarding monitoring and patient education steps, multifunctional 
experience in both technical and clinical tasks of the chemotherapy 
pharmacists seemed to contribute to monitoring medication therapy for 
team-performance improvement. While nurses were in the position to 
frequently communicate with outpatients for outpatient medication 
education and counseling, the chemotherapy pharmacists supported the 
nurses' activities utilizing MARs and the pharmacy computer system with 
pharmacy patient profiles and drug information database. 
Figure 10 illustrates value-creating flow of pharmacist activities in 
monitoring and patient education steps.  
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Figure 10. Added-value of service-oriented pharmacist and knowledge 
management model 
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The flow to utilize existing data in information systems and experience in 
operations seems to be the same as those in SECI model.  
SECI model is a conceptual model of knowledge management, proposed by 
Nonaka and Takeuchi in Japan and introduced to the US and Europe. (*16) 
According to Nonaka and Takeuchi, knowledge creation is a spiraling process 
of interactions between explicit and tacit knowledge. The interactions 
between the explicit and tacit knowledge lead to the creation of new 
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knowledge. The combination of the two categories makes it possible to 
conceptualize four conversion patterns: socialization, externalization, 
combination and internalization. Socialization refers to a process of 
acquiring tacit knowledge through sharing experiences. Externalization 
refers to a process of converting tacit knowledge into explicit concepts 
through the use of abstractions, metaphors, analogies, or models. 
Combination refers to a process of creating explicit knowledge by bringing 
together explicit knowledge from a number of sources. Internalization refers 
to a process of embodying explicit knowledge, internalizing the experience 
gained through the other modes of knowledge creation into individuals’ tacit 
knowledge basis in the form of shared mental models or work practices. 
SECI model has been widely used to analyze intangible values of knowledge 
workers and is applicable to health care practitioners.  
It seems that intangible values generated by pharmacist activities in 
monitoring and patient education steps can be examined by applying SECI 
model. Identification and quantification of intangible values also seems to 
contribute to economic evaluation studies regarding use of drug information 
database and other medical information systems. 
In addition, if knowledge and experience of pharmacists in outpatient 
chemotherapy can be shared with practitioners of other hospitals, 
point-of-care pharmacist activities will contribute to the efficiency and 
effectiveness improvement in the Japanese healthcare industry. 
 
4.3 Needs for development of economic evaluation models from Japan 
 
It is interesting to note that the QFD model, the kanban-style model and the 
SECI model were originated from Japan and have been widely adopted by 
researchers overseas. From the viewpoints of health economics, it seems that 
implementation and integration of Japan-oriented models in future 
quantitative studies will lead to appropriate evaluation of outcomes and 
evidence on pharmacist activities in outpatient chemotherapy in Japan.  
In addition, it is possible that those Japan-oriented models will be applicable 
to qualify and quantify a wide range of team care activities. The Japanese 
health care industry is populated by dedicated professionals with knowledge 
and skills, and can demonstrate a capacity to develop and implement 
standard models from inside. 
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CHAPTER 5 
Conclusion 
 
5.1 Limitation 
 
The results of this study may not be applicable to other hospital-based 
practices in Japan and qualitative approaches have challenges in gathering 
quantified generalizable data. However, such a case study is essential to 
minimize possible misunderstandings by key decision makers on health 
economics concerning the pharmacist's role in complicated multidisciplinary 
team care and in order to enhance quantitative evaluation studies with 
regard to outpatient chemotherapy team care in Japan. 
 
5.2 Conclusion 
 
The study suggests that pharmacist’s commitment to medication-use 
processes for outpatient chemotherapy at the point of care can contribute to 
improvement in the quality of care and reduction of preventable costs 
associated with medication-related problems in team care by controlling the 
product flow and information flow from both product-focused and 
service-focused perspectives. 
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